BURLINGTON, Mass. – June 27, 2016 – inVentiv Health Inc., a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced that it was selected by Pfizer Inc. (“Pfizer”) as one of its preferred partners in the delivery of clinical operations services to support Pfizer's portfolio.
inVentiv Health – comprised of a top-tier CRO and the industry’s only Contract Commercial Organization (CCO) – is now a preferred partner in Pfizer’s sourcing strategy for global clinical operations services. The agreement term is until June 8, 2019 and provides Pfizer with the right to extend the term for up to an additional two years. Financial terms of the agreement were not disclosed.
"Complex science and challenging marketplace dynamics are driving the need for new, accelerated approaches to clinical development,” said Michael McKelvey, Ph.D., President of the Clinical Division at inVentiv Health. “This agreement is an indication that our leading full-service clinical offerings are value-enhancing and scalable. We designed this approach to deliver patient-centric outcomes in an increasingly competitive environment."
As a preferred provider, inVentiv has expanded its clinical operations presence with Pfizer and is focused on therapeutic excellence in the areas of oncology, pain, neuroscience and respiratory and data and technology-driven efficiencies.
"Our comprehensive clinical services have proved to be an asset in our work with Pfizer,” said Gregory Skalicky, Chief Commercial Officer, inVentiv Health Clinical Division. “The expansion of our relationship under this new preferred provider status will allow us to continue to seamlessly orchestrate our full suite of clinical solutions. We’re committed to realizing improved efficiencies in support of Pfizer’s clinical development activities."